Studies to explore how myrcene, other cannabinoid-based ingredients can treat chronic-neuropathic pain Amid growing public and government concerns regarding opioid use, GBS Global Biopharma, Inc. will conduct preclinical studies on its proprietary chronic-neuropathic pain formulations in collaboration with National Research Council Canada (NRC). “Providing sustained relief from chronic-neuropathic pain would bring quality of life to tens of millions of patients throughout the world who suffer from conditions such as … peripheral neuropathy.” Learn more. |